Two randomized, placebo-controlled, phase III trials have shown sorafenib, an oral multitarget inhibitor, to be effective in these patients. 2,3 In the Sorafenib Hepatocellular Carcinoma ...

The side effects are manageable and consist of rash or acne and diarrhea. Sorafenib is an oral multikinase inhibitor of angiogenesis and cellular proliferation, with its anticancer effect deriving ...

Get detailed information on Sorafenib, including pronunciation ... This medication is a kinase inhibitor, prescribed for renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver ...

In their contribution, Ivanyi et al. discuss the potential cardiotoxic side effects of the tyrosine kinase inhibitors sunitinib and sorafenib. They describe the side effect of this treatment ...